ADC specialist Tubulis expanded its Series C to $401 million with an additional $40 million injection two weeks after closing the original tranche. The Munich‑based company said the funds will accelerate development and scale of its next‑generation antibody‑drug conjugate platform. Investors appear to be rewarding Tubulis’s platform approach and the promise of differentiated ADC modalities that aim to improve therapeutic index and manufacturability. The capital raise positions Tubulis to advance multiple preclinical and early clinical programs and to invest in process development. For the ADC field, the round signals continued investor confidence in platform companies building modular linker/payload and targeting technologies despite a selective late‑stage clinical environment.